Article
Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.
The New England journal of medicine - 9 Apr 2026
Park Wungki, Kasi Anup, Spira Alexander I, Paz-Ares Rodríguez Luis, Herzberg Benjamin O, Pelster Meredith S, Tolcher Anthony W, Kuboki Yasutoshi, Kitano Shigehisa, Shoji Hirokazu, Wang Judy S, Berlin Jordan D, Hollebecque Antoine, LoRusso Patricia, Fountzilas Christos, Cassier Philippe A, Nishina Tomohiro, Sakai Daisuke, Inagaki Chiaki, Morgensztern Daniel, Ueno Makoto, Jung Minkyu, Kim Sang-We, Jänne Pasi A, Italiano Antoine, You Benoît, Macarulla T, Fujii Hisaki, Shetty Aditya, Lu Ying, Cui Daniel, Kadam Shilpa, Gill Stanley C, Toyoshima Junko, Saito Takeshi, Goldman Jonathan W
Abstract excerpt
BACKGROUND: The KRAS p.G12D variant occurs in 5% of patients with non-small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, but no targeted therapies directed against this variant are currently approved for clinical use. Setidegrasib (ASP3082) is a first-in-class KRAS G12D-targeted protein degrader. METHODS: We conducted this...
Topics
Join the communities discussing this publication.